Positive Results For Peplin’s Phase IIb AK Trial

Peplin, Inc. (ASX:PLI) announced positive results with its lead product candidate PEP005 (ingenol mebutate) Gel in its Phase IIb actinic (solar) keratosis (AK) dose ranging clinical trial (PEP005-015) for the treatment of AK lesions on head locations, which comprise the face and scalp. AK is a common pre-cancerous skin condition caused by sun exposure. The face is the most common area for sun damage and the most common area for AK’s, which can develop into skin cancers if left untreated.

More: continued here

Filed under: Dermatology on January 14th, 2009